Viewing Study NCT07446335


Ignite Creation Date: 2026-03-26 @ 3:17 PM
Ignite Modification Date: 2026-03-29 @ 11:35 PM
Study NCT ID: NCT07446335
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-03
First Post: 2026-02-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
Sponsor: The First Affiliated Hospital of Zhengzhou University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module